Seattle Genetics, Inc. (SGEN) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC lessened its position in Seattle Genetics, Inc. (NASDAQ:SGEN) by 53.7% during the third quarter, according to the …

Seattle Genetics logoAQR Capital Management LLC lessened its position in Seattle Genetics, Inc. (NASDAQ:SGEN) by 53.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,532 shares of the biotechnology company’s stock after selling 19,143 shares during the quarter. AQR Capital Management LLC’s holdings in Seattle Genetics were worth $1,275,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd bought a new position in Seattle Genetics in the third quarter valued at $104,000. Hollencrest Capital Management bought a new position in Seattle Genetics in the third quarter valued at $216,000. Fox Run Management L.L.C. bought a new position in Seattle Genetics in the third quarter valued at $225,000. Cornerstone Wealth Management LLC bought a new position in Seattle Genetics in the third quarter valued at $250,000. Finally, Verition Fund Management LLC bought a new position in Seattle Genetics in the third quarter valued at $261,000.

NASDAQ SGEN opened at $73.61 on Tuesday. Seattle Genetics, Inc. has a 12-month low of $47.75 and a 12-month high of $84.37. The stock has a market cap of $11.79 billion, a price-to-earnings ratio of -83.65 and a beta of 2.04.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, October 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.15). The business had revenue of $169.42 million for the quarter, compared to analysts’ expectations of $164.75 million. Seattle Genetics had a negative net margin of 26.58% and a negative return on equity of 19.13%. As a group, equities research analysts anticipate that Seattle Genetics, Inc. will post -1.44 EPS for the current year.

Several analysts have issued reports on SGEN shares. restated a “hold” rating on shares of Seattle Genetics in a research report on Monday, October 1st. Piper Jaffray Companies cut their price target on shares of Seattle Genetics to $66.00 and set a “neutral” rating for the company in a research report on Thursday, October 25th. TheStreet lowered shares of Seattle Genetics from a “c” rating to a “d+” rating in a research report on Thursday, October 25th. BidaskClub lowered shares of Seattle Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. Finally, Royal Bank of Canada upped their price target on shares of Seattle Genetics to $98.00 and gave the company an “outperform” rating in a research report on Tuesday, October 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $79.75.

In other news, EVP Darren S. Cline sold 7,000 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $62.88, for a total transaction of $440,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Clay B. Siegall sold 20,148 shares of the stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $65.73, for a total transaction of $1,324,328.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 81,611 shares of company stock valued at $5,080,123. 33.80% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Seattle Genetics, Inc. (SGEN) Shares Sold by AQR Capital Management LLC” was originally posted by Modern Readers and is the sole property of of Modern Readers. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.modernreaders.com/news/2019/01/22/seattle-genetics-inc-sgen-shares-sold-by-aqr-capital-management-llc.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Featured Story: Capital Gains

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Seattle Genetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Bonanza Creek Energy Inc (NYSE:BCEI) Holdings Boosted by BlackRock Inc.

BlackRock Inc. grew its position in Bonanza Creek Energy Inc (NYSE:BCEI) by 92.3% during the third quarter, according to the company in its most …

Bonanza Creek Energy logoBlackRock Inc. grew its position in Bonanza Creek Energy Inc (NYSE:BCEI) by 92.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,774,826 shares of the oil and gas producer’s stock after purchasing an additional 1,331,837 shares during the period. BlackRock Inc. owned approximately 13.51% of Bonanza Creek Energy worth $82,633,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new stake in Bonanza Creek Energy during the second quarter worth $245,000. State of Alaska Department of Revenue bought a new stake in Bonanza Creek Energy during the third quarter worth $200,000. BlueMountain Capital Management LLC bought a new position in shares of Bonanza Creek Energy in the 2nd quarter valued at $268,000. Louisiana State Employees Retirement System bought a new position in shares of Bonanza Creek Energy in the 3rd quarter valued at $244,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Bonanza Creek Energy in the 3rd quarter valued at $256,000.

Shares of NYSE:BCEI opened at $24.70 on Tuesday. Bonanza Creek Energy Inc has a 12-month low of $18.41 and a 12-month high of $40.38. The firm has a market cap of $507.43 million, a P/E ratio of 5.20 and a beta of 1.54.

Bonanza Creek Energy (NYSE:BCEI) last issued its quarterly earnings results on Thursday, November 8th. The oil and gas producer reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.06 by $1.04. Bonanza Creek Energy had a return on equity of 13.67% and a net margin of 21.61%. The firm had revenue of $74.38 million during the quarter, compared to the consensus estimate of $68.59 million. On average, equities research analysts anticipate that Bonanza Creek Energy Inc will post 3.06 earnings per share for the current year.

BCEI has been the subject of a number of research reports. Zacks Investment Research upgraded Bonanza Creek Energy from a “hold” rating to a “strong-buy” rating and set a $25.00 price target for the company in a research note on Thursday, January 3rd. SunTrust Banks initiated coverage on Bonanza Creek Energy in a research note on Friday, December 14th. They issued a “hold” rating and a $25.00 price target for the company. Finally, Imperial Capital raised their target price on Bonanza Creek Energy to $53.00 in a research report on Friday, October 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Bonanza Creek Energy currently has a consensus rating of “Buy” and a consensus target price of $36.00.

ILLEGAL ACTIVITY NOTICE: “Bonanza Creek Energy Inc (NYSE:BCEI) Holdings Boosted by BlackRock Inc.” was reported by Fairfield Current and is the property of of Fairfield Current. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/22/blackrock-inc-grows-stake-in-bonanza-creek-energy-inc-bcei.html.

Bonanza Creek Energy Company Profile

Bonanza Creek Energy, Inc engages in the exploration, development, and production of onshore oil and related liquids-rich natural gas in the United States. The company’s oil and liquids-weighted assets are located primarily in the Wattenberg Field in Colorado; and the Dorcheat Macedonia Field in southern Arkansas.

Recommended Story: How can you know how many shares are floating?

Institutional Ownership by Quarter for Bonanza Creek Energy (NYSE:BCEI)

Receive News & Ratings for Bonanza Creek Energy Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bonanza Creek Energy and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

AQR Capital Management LLC Increases Holdings in Noble Energy, Inc. (NYSE:NBL)

AQR Capital Management LLC raised its position in shares of Noble Energy, Inc. (NYSE:NBL) by 887.5% during the third quarter, according to its most …

Noble Energy logoAQR Capital Management LLC raised its position in shares of Noble Energy, Inc. (NYSE:NBL) by 887.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 202,857 shares of the oil and gas development company’s stock after purchasing an additional 182,314 shares during the period. AQR Capital Management LLC’s holdings in Noble Energy were worth $6,327,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Chicago Equity Partners LLC acquired a new position in Noble Energy in the 2nd quarter worth about $204,000. BB&T Corp bought a new position in Noble Energy in the third quarter worth approximately $211,000. Lourd Capital LLC bought a new position in Noble Energy in the third quarter worth approximately $220,000. Raymond James Trust N.A. bought a new position in Noble Energy in the third quarter worth approximately $231,000. Finally, Fulton Bank N.A. bought a new position in Noble Energy in the third quarter worth approximately $235,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

NBL has been the topic of several recent research reports. Piper Jaffray Companies reiterated an “overweight” rating on shares of Noble Energy in a report on Friday, September 28th. Oppenheimer began coverage on Noble Energy in a research note on Wednesday, October 3rd. They issued a “market perform” rating and a $43.00 price objective for the company. Morgan Stanley set a $38.00 price objective on Noble Energy and gave the stock a “hold” rating in a research note on Friday, October 12th. Stifel Nicolaus set a $46.00 price objective on Noble Energy and gave the stock a “buy” rating in a research note on Thursday, November 1st. Finally, TD Securities decreased their price target on Noble Energy from $42.00 to $39.00 and set a “buy” rating for the company in a research report on Friday, November 2nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twenty-one have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $40.13.

NYSE NBL traded up $0.20 during trading hours on Monday, reaching $23.39. 6,683,608 shares of the stock traded hands, compared to its average volume of 5,537,658. Noble Energy, Inc. has a 1 year low of $17.11 and a 1 year high of $37.76. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $11.22 billion, a price-to-earnings ratio of 75.45, a PEG ratio of 1.01 and a beta of 1.26.

Noble Energy (NYSE:NBL) last released its quarterly earnings results on Thursday, November 1st. The oil and gas development company reported $0.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.18 by $0.09. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.16 billion. Noble Energy had a return on equity of 4.82% and a net margin of 25.09%. The company’s revenue for the quarter was up 32.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) earnings per share. On average, equities analysts expect that Noble Energy, Inc. will post 0.95 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AQR Capital Management LLC Increases Holdings in Noble Energy, Inc. (NYSE:NBL)” was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/22/noble-energy-inc-nbl-shares-bought-by-aqr-capital-management-llc.html.

Noble Energy Company Profile

Noble Energy, Inc, an independent energy company, engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids worldwide. It owns, operates, develops, and acquires domestic midstream infrastructure assets in the DJ and Delaware Basins. It principal projects are primarily located in the US unconventional basins and various global offshore conventional basins.

Read More: How is inflation measured?

Institutional Ownership by Quarter for Noble Energy (NYSE:NBL)

Receive News & Ratings for Noble Energy Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Noble Energy and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Infosys (INFY) Earning Somewhat Favorable Press Coverage, InfoTrie Reports

News articles about Infosys (NYSE:INFY) have trended somewhat positive on Monday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage …

Infosys logoNews articles about Infosys (NYSE:INFY) have trended somewhat positive on Monday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Infosys earned a news sentiment score of 1.25 on their scale. InfoTrie also assigned headlines about the technology company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock’s share price in the near term.

Here are some of the news headlines that may have impacted Infosys’ ranking:

Infosys stock traded up $0.09 during midday trading on Monday, reaching $10.67. The company’s stock had a trading volume of 10,168,668 shares, compared to its average volume of 11,357,851. Infosys has a 52 week low of $8.24 and a 52 week high of $10.69. The stock has a market cap of $46.37 billion, a PE ratio of 21.34, a P/E/G ratio of 2.07 and a beta of 0.42.

The firm also recently announced a dividend, which will be paid on Friday, January 25th. Shareholders of record on Friday, January 25th will be given a $0.047 dividend. The ex-dividend date of this dividend is Thursday, January 24th. Infosys’s dividend payout ratio is presently 34.00%.

Several equities research analysts have issued reports on INFY shares. Zacks Investment Research downgraded Infosys from a “hold” rating to a “sell” rating in a report on Tuesday, December 18th. Citigroup raised Infosys from a “neutral” rating to a “buy” rating in a report on Friday, January 4th. Wedbush dropped their target price on Infosys from $18.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, November 27th. ValuEngine raised Infosys from a “sell” rating to a “hold” rating in a report on Tuesday, October 2nd. Finally, Wells Fargo & Co set a $11.00 target price on Infosys and gave the stock a “hold” rating in a report on Friday, January 11th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $12.75.

ILLEGAL ACTIVITY NOTICE: “Infosys (INFY) Earning Somewhat Favorable Press Coverage, InfoTrie Reports” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/01/22/infosys-infy-receives-media-impact-score-of-1-25.html.

Infosys Company Profile

Infosys Limited, together with its subsidiaries, provides consulting, technology, and outsourcing services in North America, Europe, India, and internationally. It provides business information technology services, including application development and maintenance, independent validation, infrastructure management, and business process management services, as well as engineering services, such as engineering and life cycle solutions; and consulting and systems integration services comprising consulting, enterprise solutions, systems integration, and advanced technologies.

Featured Article: What is the Current Ratio?

Insider Buying and Selling by Quarter for Infosys (NYSE:INFY)

Receive News & Ratings for Infosys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Infosys and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

MacroGenics Inc (MGNX) Holding Lowered by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its position in MacroGenics Inc (NASDAQ:MGNX) by 41.6% in the third quarter, according to the company in …

Renaissance Technologies LLC lowered its position in MacroGenics Inc (NASDAQ:MGNX) by 41.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 159,023 shares of the biopharmaceutical company’s stock after selling 113,376 shares during the period. Renaissance Technologies LLC owned about 0.38% of MacroGenics worth $3,409,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Keybank National Association OH bought a new position in MacroGenics during the 3rd quarter worth about $203,000. Hussman Strategic Advisors Inc. bought a new position in MacroGenics during the 3rd quarter worth about $214,000. Metropolitan Life Insurance Co. NY increased its holdings in MacroGenics by 33.7% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 13,178 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 3,323 shares in the last quarter. MetLife Investment Advisors LLC increased its holdings in MacroGenics by 26.1% during the 2nd quarter. MetLife Investment Advisors LLC now owns 18,661 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 3,858 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in MacroGenics by 33.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 22,200 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 5,600 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

MGNX has been the subject of several analyst reports. Zacks Investment Research cut MacroGenics from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. BidaskClub cut MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday. HC Wainwright set a $34.00 price objective on MacroGenics and gave the company a “buy” rating in a report on Wednesday, December 5th. ValuEngine cut MacroGenics from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. Finally, Morgan Stanley set a $21.00 price objective on MacroGenics and gave the company a “hold” rating in a report on Monday, December 10th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. MacroGenics currently has a consensus rating of “Buy” and an average target price of $30.29.

Shares of NASDAQ MGNX opened at $12.31 on Monday. The stock has a market capitalization of $520.21 million, a PE ratio of -22.80 and a beta of 2.55. MacroGenics Inc has a fifty-two week low of $11.16 and a fifty-two week high of $32.74.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.48. The company had revenue of $20.80 million during the quarter, compared to analysts’ expectations of $6.18 million. MacroGenics had a negative return on equity of 7.39% and a negative net margin of 10.72%. On average, sell-side analysts expect that MacroGenics Inc will post -4.18 earnings per share for the current fiscal year.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.

Read More: How To Calculate Debt-to-Equity Ratio

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).

Related Posts:

  • No Related Posts